Updated:
Revvity
Revvity, led by CEO Prahlad Singh, is the $2.7B revenue diagnostics and drug-discovery tools spinout from the 2023 PerkinElmer breakup.
Revvity
Revvity was formed in May 2023 when PerkinElmer sold its applied, food, and enterprise services businesses to New Mountain Capital for $2.45 billion, retaining the life-sciences and diagnostics segments under a new name and NYSE ticker (RVTY). CEO Prahlad Singh, who previously ran PerkinElmer, stayed on to lead the narrower entity. The wealth origin is purely corporate — a publicly traded C-corp with no single-family backing — and its capital comes from operations and public equity markets, not a family pool. The firm deploys capital across diagnostics, life-sciences reagents, and laboratory software. Its strategy centers on bolt-on acquisitions that expand its installed base of automated liquid handlers, plate readers, and high-content screening systems — instruments that generate recurring consumables revenue. Geography spans North America, Europe, and Asia-Pacific, with a growing emphasis on China's contract-research market. Confirmed acquisitions include BioLegend for $5.25 billion in 2021 (pre-rebrand, per the firm, 2021) and more recent tuck-ins in cellular analysis and immunoassay multiplexing. In 2024, Revvity divested several smaller non-core assets to further sharpen its focus, leaving it a pure-play tools company generating roughly $2.7 billion in annual revenue with a market capitalization above $14 billion. It maintains joint ventures in Japan and distribution partnerships across emerging markets. Adjacent vehicles include the Revvity Foundation, which funds STEM education and global health programs, structurally separate from commercial operations. The structural differentiator is a pure-play conviction in a single industry vertical. Unlike diversified tool peers, Revvity exited every non-life-science business in one transaction, creating a balance sheet entirely hostage to pharmaceutical R&D spending. That concentration allows it to price instruments and service contracts against a specific lab economics model, but leaves it without the cyclical hedge that food-testing or industrial segments provide to competitors like Thermo Fisher.
General information
Firm type
Asset Manager
Year founded
1937
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Waltham
Corporate office
Waltham, MA, United States
Principals
Prahlad Singh
President and Chief Executive Officer
Sector focus
Frequently asked questions
What was the rationale behind the PerkinElmer breakup, and how does it shape Revvity's investment profile?
Management concluded that the applied-markets and diagnostics businesses had diverging capital-allocation priorities and investor bases. By selling the applied segment for $2.45 billion and rebranding as Revvity, the remaining entity could reinvest proceeds entirely into life-science tools without cross-subsidizing slower-growth industrial divisions. The result is a streamlined acquirer focused on lab automation, immunodiagnostics, and preclinical software.
How does Revvity source M&A targets?
Deal flow originates primarily through relationships with venture-backed life-science startups and academic spinouts developed over PerkinElmer's multi-decade instrument-installed base. Revvity typically acquires companies whose assays or software complement its existing automation platforms, often identifying targets after they achieve regulatory clearance but before they build independent commercial scale.
Is Revvity a single-family office or a traditional corporate?
Revvity is a publicly traded corporation (NYSE: RVTY) with no family-office structure. It is an operating company that manufactures and sells scientific instruments, reagents, and software. Institutional investors own the vast majority of its equity; no single family controls the board or investment decisions.
What is Revvity's exposure to pharmaceutical R&D spending cycles?
Roughly 85% of revenue ties directly to pharmaceutical and biotech R&D budgets, making Revvity more cyclically exposed than diversified tools peers. During pharma pipeline contractions, consumables pull-through and instrument orders have historically declined; conversely, strong NME approval cycles drive growth in its high-content screening and automation divisions.
Does Revvity participate in fund commitments or operate as a limited partner?
No. Revvity does not commit capital to external venture or private equity funds. Corporate venture activities are conducted through discrete technology licensing agreements and occasional minority equity stakes in firms whose platforms it may eventually acquire.
How does the BioLegend acquisition fit into Revvity's longer-term strategy?
The $5.25 billion BioLegend acquisition, closed in late 2021 while still operating as PerkinElmer, added a high-growth, high-margin antibody and reagent franchise with a direct channel to immunology researchers. Post-rebrand, BioLegend remains Revvity's flagship protein-biology platform, and the management team that built it was retained to drive further organic expansion in multiplexed proteomics.
Which sectors does Revvity explicitly avoid?
Revvity explicitly avoids applied markets — food safety testing, environmental analysis, and industrial quality control — which was the entire segment sold to New Mountain Capital. It also does not manufacture therapeutic drugs or provide clinical care, staying strictly on the tools-and-software side of life sciences.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: